Casirivimab and Imdevimab for the Treatment of Hospitalized Patients With COVID-19Clinical Trial Published on 2022-12-282023-07-10 Journal: The Journal of Infectious Diseases [Category] COVID19(2023년), [키워드] coronavirus COVID-19 Hospitalized monoclonal antibody. SARS-CoV-2 [DOI] 10.1093/infdis/jiac320 PMC 바로가기 [Article Type] Clinical Trial
Limited Impact of SARS-CoV-2 on the Human Naso-Oropharyngeal Microbiota in Hospitalized PatientsArticle Published on 2022-12-212023-07-10 Journal: Microbiology Spectrum [Category] COVID19(2023년), [키워드] 16S rRNA COVID-19 Hospitalized naso-oropharyngeal microbiome. SARS-CoV-2 [DOI] 10.1128/spectrum.02196-22 PMC 바로가기
Casirivimab and Imdevimab Treatment Reduces Viral Load and Improves Clinical Outcomes in Seropositive Hospitalized COVID-19 Patients with Nonneutralizing or Borderline Neutralizing AntibodiesRandomized Controlled Trial Published on 2022-12-202023-07-10 Journal: mBio [Category] COVID19(2023년), [키워드] anti-SARS-CoV-2 serostatus casirivimab and imdevimab COVID-19 Hospitalized monoclonal antibodies neutralizing antibodies. [DOI] 10.1128/mbio.01699-22 PMC 바로가기 [Article Type] Randomized Controlled Trial
Changes of Routine Hematological Parameters in COVID-19 Patients: Correlation with Imaging Findings, RT-PCR and OutcomeOriginal Article Published on 2022-12-152022-10-29 Journal: Iranian Journal of Pathology [Category] COVID-19, [키워드] Admission age analyses Biochemical parameters Blood change Chest chest imaging Chest tomography Concentration Coronavirus disease 2019 correlated correlation correlations COVID-19 COVID-19 case COVID-19 patient Critical CRP CT-scan demonstrated diagnosed Diagnosis during admission enrolled evaluated expired group hematologic hematology hemoglobin Hospitalized imaging investigated Laboratory LDH less leukocyte lung lung involvement Lymphocytes neutrophil no increase outcome parameter parameters participant Patient patients Platelet platelets count Prognostic value raise researcher respiratory viral routine RT-PCR severity Severity of disease the disease tomography Tomography scanners upper respiratory Viral load WBC were measured White blood cells [DOI] 10.30699/IJP.2021.533645.2675 PMC 바로가기 [Article Type] Original Article
COVID-19 treatments approved in the European Union and clinical recommendations for the management of non-hospitalized and hospitalized patientsArticle Published on 2022-12-012022-11-15 Journal: Annals of Medicine [Category] COVID19(2023년), SARS, 진단, 치료제, [키워드] addition affecting alleviate antiviral medication antiviral medicine approved Baricitinib Care caused Clinical practice clinical recommendations Community courses COVID-19 COVID-19 pandemic COVID-19 patient COVID-19 treatment COVID-19 treatments Critical deaths develop disease disorder drug Dyspnea effective effective drugs European European Medicines Agency European Union Evidence guidelines. Health healthcare hospital Hospitalization Hospitalized hospitalized patient hypoxia Intervention involved life-threatening lung involvement management Mild moderate molnupiravir monoclonal antibodies monoclonal antibody Most patient Multiorgan dysfunction New outcome public health recommendation Remdesivir Respiratory failure rheumatoid arthritis SARS-CoV-2 Septic shock severe symptom Symptom the disease the patient therapy Thromboembolism Tocilizumab treat Treatment treatment strategy union vaccination [DOI] 10.1080/07853890.2022.2133162 PMC 바로가기
Severity of SARS-CoV-2 Omicron BA.2 infection in unvaccinated hospitalized children: comparison to influenza and parainfluenza infections예방접종을 받지 않은 입원 소아에서 SARS-CoV-2 Omicron BA.2 감염의 심각도: 인플루엔자 및 파라인플루엔자 감염과의 비교Article Published on 2022-12-012022-09-11 Journal: Emerging Microbes & Infections [Category] COVID19(2023년), SARS, 변종, [키워드] 95%CI acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 adjusted Admission children Clinical outcome coronavirus COVID-19 COVID-19 infection Croup database death had no hospitalisation hospitalisations Hospitalization Hospitalized Infection Influenza Influenza virus initial investigated Mild neurological Neurological complication Neurological complications occurred omicron outcome parainfluenza parainfluenza virus proportion Public Hospital Relative risk required respiratory. retrieved risk SARS-CoV-2 severe acute respiratory syndrome Coronavirus severity uninfected upper airway upper airways vaccination variant viral infections virus viruses were recorded [DOI] 10.1080/22221751.2022.2093135 PMC 바로가기 [Article Type] Article
Altered kidney function induced by SARS-CoV-2 infection and acute kidney damage markers predict survival outcomes of COVID-19 patients: a prospective pilot studySARS-COV-2 감염 및 급성 신장 손상 마커에 의해 유도 된 변경된 신장 기능 COVID-19 환자의 생존 결과를 예측합니다 : 전향 적 파일럿 연구Article Published on 2022-12-012022-08-31 Journal: Renal failure [Category] COVID19(2023년), SARS, 바이오마커, [키워드] acute kidney Acute kidney injury adjusted Advancing age Altered Analysis association Biomarker chronic Chronic kidney disease collaboration Comorbidities Comorbidity Control coronavirus disease Coronavirus disease 2019 covariate covariates COVID-19 COVID-19 patient COVID-19 patients creatinine Cumulative rates cystatin C death demonstrated elevated examined group groups Hospitalized ICU intensive care intensive care unit investigated Kaplan-Meier method kidney kidney damage Kidney disease Kidney function Kidney function tests Kidney injury literature marker morbidity multivariable Cox regression outcome participant pilot study predict Predictive Predictive value Proteinuria retained risk factor Risk factors SARS-COV-2 infection serum serum creatinine Sex significant difference statistically subject survival survival analysis survival analysis. the Kaplan-Meier method Treatment Urine with COVID-19 [DOI] 10.1080/0886022X.2022.2032743 PMC 바로가기 [Article Type] Article
Disease severity and efficacy of homologous vaccination among patients infected with SARS-CoV-2 Delta or Omicron VOCs, compared to unvaccinated using main biomarkersArticle Published on 2022-12-012022-11-15 Journal: Journal of medical virology [Category] COVID19(2023년), SARS, 바이오마커, 변종, 진단, [키워드] AstraZeneca Biomarker booster case-control study caused Chronic diseases Clinical severity conducted country COVID-19 COVID-19 confirmed patient COVID-19 patient COVID-19 vaccination COVID-19 vaccine CRP level Delta delta variant Delta wave dose doses effective Effectiveness Efficacy expressed females Health homologous homologous vaccination. hospital Hospitalization Hospitalized individual infected with SARS-CoV-2 Iraq Lower males molecular no significant difference no significant effect omicron Omicron variant pandemic Patient patients Pfizer Population Prevent recommendation recorded risk SARS-CoV-2 SARS-CoV-2 pandemic SARS-CoV-2 variant severity significantly Symptom the disease the vaccine transmissibility of SARS-CoV-2 vaccination Vaccine variant variants of concern virus VOCs was done WBC [DOI] 10.1002/jmv.28098 PMC 바로가기
An open, prospective cohort study of VV116 in Chinese participants infected with SARS-CoV-2 omicron variantsSARS-CoV-2 오미크론 변이체에 감염된 중국 참가자의 VV116에 대한 공개, 전향적 코호트 연구Article Published on 2022-12-012022-09-11 Journal: Emerging Microbes & Infections [Category] COVID19(2023년), SARS, 변종, [키워드] adjusted administration adverse event adverse events anti-SARS-CoV-2 antiviral drug baseline characteristics Chinese Cohort cohort study collected conducted control group COVID-19 Cox regression analysis effective Effectiveness Efficacy enrolled evaluate first positive Follow-up Hospitalized infected with SARS-CoV-2 Infection Intervention median time no significant difference omicron Omicron variant participant Patient preclinical studies predominant Prevalence prospective cohort study receive regression analysis reported resolved robust Safe Serious Adverse Event Serious Adverse Events standard treatment Symptom symptomatic treatment group variant variant of SARS-CoV-2 Viral load Viral load. viral shedding VV116 with COVID-19 [DOI] 10.1080/22221751.2022.2078230 PMC 바로가기 [Article Type] Article
Identification of CKD, bedridden history and cancer as higher-risk comorbidities and their impact on prognosis of hospitalized Omicron patients: a multi-centre cohort studyArticle Published on 2022-12-012022-11-16 Journal: Emerging Microbes & Infections [Category] COVID19(2023년), SARS, 치료기술, [키워드] advanced age age Cancer China Chronic kidney disease CKD cohort study Comorbidity condition conditions COVID-19 critical cases enrolled Factor female first positive hospialized population Hospitalized hospitalized patient hypertension identification Logistic regression Metabolic disorders multivariate Observational cohort study omicron participant Patient patients Primary outcome Prognosis progression risk factor Risk factors Risk factors. SARS-CoV-2 SARS-CoV-2 detection secondary outcome severity Shanghai suggested vaccination viral shedding [DOI] 10.1080/22221751.2022.2122581 PMC 바로가기